Tempest Therapeutics Secures $4.25M in Direct Offering

The latest update is out from Tempest Therapeutics ( (TPST) ).

On November 24, 2025, Tempest Therapeutics entered into a securities purchase agreement with a healthcare-focused institutional investor to issue and sell shares of common stock and warrants in a registered direct offering and a concurrent private placement. The offering, expected to close on November 26, 2025, is anticipated to generate gross proceeds of approximately $4.25 million, with potential additional proceeds from warrant exercises. The company plans to use the funds for working capital and general corporate purposes, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.

Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.

To see Spark’s full report on TPST stock, click here.

More about Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company based in Brisbane, California, focusing on developing a diverse portfolio of small molecule product candidates with tumor-targeted and immune-mediated mechanisms aimed at treating a wide range of tumors.

Average Trading Volume: 89,941

Technical Sentiment Signal: Strong Sell

Current Market Cap: $14.21M

For a thorough assessment of TPST stock, go to TipRanks’ Stock Analysis page.